EP1708754A2 - Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb - Google Patents

Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb

Info

Publication number
EP1708754A2
EP1708754A2 EP04803903A EP04803903A EP1708754A2 EP 1708754 A2 EP1708754 A2 EP 1708754A2 EP 04803903 A EP04803903 A EP 04803903A EP 04803903 A EP04803903 A EP 04803903A EP 1708754 A2 EP1708754 A2 EP 1708754A2
Authority
EP
European Patent Office
Prior art keywords
imidazoline
mixture
solvates
stereoisomers
ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04803903A
Other languages
German (de)
English (en)
Inventor
Gerd Bartoszyk
Christoph Van Amsterdam
Henning Boettcher
Christoph Seyfried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1708754A2 publication Critical patent/EP1708754A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to combinations of serotonin reuptake inhibitors (SRIs) and imidazoline agonists as separate chemical units or both properties combined in one molecule and their use for the manufacture of medicaments for the treatment of depression, obsessive compulsive disorders disorders, OCD), obsessive compulsive spectrum disorders (OCSD) and other anxiety disorders.
  • SRIs serotonin reuptake inhibitors
  • imidazoline agonists as separate chemical units or both properties combined in one molecule and their use for the manufacture of medicaments for the treatment of depression, obsessive compulsive disorders disorders, OCD), obsessive compulsive spectrum disorders (OCSD) and other anxiety disorders.
  • Serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, fluvoxamine or citalopram are standard therapeutic agents for the treatment of depression such as unipolar depression, bipolar depression, dysthymia or secondary-occurring depression in connection with physical illnesses, obsessive-compulsive disorder (obsessive-spectrum disorders) e.g. Pigott TA, Seay SM (1999) J Clin Psychiatry 60: 101-106) and other anxiety conditions such as generalized anxiety, post-traumatic stress disorder, social anxiety or panic disorder.
  • depression such as unipolar depression, bipolar depression, dysthymia or secondary-occurring depression in connection with physical illnesses, obsessive-compulsive disorder (obsessive-spectrum disorders) e.g. Pigott TA, Seay SM (1999) J Clin Psychiatry 60: 101-106) and other anxiety conditions such as generalized anxiety, post-traumatic stress disorder, social anxiety or panic disorder.
  • Imidazoline l 2 agonists such as 2-BFI, LSL 60101, LSL 61122, BU224,
  • the first selective Imidazoline I 2 agonist is 2-BFI (2- (2-benzofuranyl) -2- imidazolines) described (eg Lione et al, Br J Pharmacol, 1995, 114:. 412P; Lione et al, Eur J Pharmacol 1996th , 304: 221-229; Coates et al., Bioorg Med Chem Lett 2000, 10: 605-607).
  • SRI serotonin reuptake inhibitor
  • 2- (2-benzofuranyl) -2-imidazoline (2-BFI) was - as in described below - examined using microdialysis studies and animal models for depression and anxiety.
  • a typical animal model for anxiety is the "marble burying test" (e.g. Njung'e and Handley, Br J Pharmacol 1991, 104: 105-112), which has specificity for obsessive-compulsive disorders and obsessive-spectrum disorders.
  • the test device consists of a cube-shaped box open at the top, in which 25 clear glass marbles are arranged at regular intervals on a 5 cm high layer of sawdust. Mice are individually placed in the test box for 30 minutes. The number of marbles buried in the sawdust during the test period of 30 minutes serves as a measure of fear. Untreated mice bury most of the marbles in the sawdust, while anxiolytics reduce the number of marbles buried.
  • a typical animal model for depression is the "forced swimming test” (RD Porsolt et al., Nature 1977; 266 (5604): 730-732), which is performed on rats.
  • This model is based on the behavior known as "behavioral despair", which the animals show in a hopeless situation known to them: if the rats are placed in a container filled with water (usually for 15 minutes) from which they cannot free themselves, after a certain time, stop trying to escape the situation and remain immobile or only make the most necessary swimming movements. If the rats are exposed to this situation again the next day, they recognize the hopelessness of the situation and now remain in immobility for the majority of the time, and the time that the animals spend in immobility during the 5-minute test period (which is considered a surrogate for depression) is used as a measure of depression. Antidepressants shorten this immobility period.
  • Fluoxetine (5 mg / kg orally) and 2-BFI (3 and 10 mg / kg orally) are - individually or combined - either after a repeated acute (fluoxetine 24 h, 5 h and 2 h; 2-BFI 24 h, 5 h and 1 h before the start of the test) or according to a subchronic (fluoxetine or 2-BFI once a day for 7 days, on the last day fluoxetine 2 h and 2-BFI 1 h before the start of the test) schedule.
  • a repeated acute fluoxetine 24 h, 5 h and 2 h; 2-BFI 24 h, 5 h and 1 h before the start of the test
  • subchronic fluoxetine or 2-BFI once a day for 7 days, on the last day fluoxetine 2 h and 2-BFI 1 h before the start of the test
  • the present invention thus relates to a substance and / or a mixture of substances which have serotonin reuptake-inhibiting and imidazoline- ⁇ - receptor agonistic properties and / or its Derivatives, stereoisomers and pharmaceutically usable derivatives, including their mixtures in all ratios.
  • the present invention relates in particular to a substance which inhibits serotonin reuptake and at the same time agonistically binds to the imidazoline-l 2 receptor.
  • the present invention furthermore relates to a substance which inhibits serotonin reuptake and, at the same time, agonistically binds to the imidazoline - ⁇ receptor, and / or a mixture of substances comprising one or more SRI and one or more imidazoline-l 2 agonists, in particular in its capacity as a medicament, as well as corresponding pharmaceutical preparations containing this mixture of substances and possibly other active pharmaceutical ingredients (preferably CNS-active ingredients).
  • the mixture of substances or the pharmaceutical preparation contains 2-BFI as SRI fluoxetine and as imidazoline agonist.
  • the invention further relates to the use of said substance and / or mixture of substances for the manufacture of a medicament for the treatment or prophylaxis of diseases in which the inhibition of serotonin reuptake and the agonistic binding of active substances to the imidazoline-l 2 receptor to improve the clinical picture leads.
  • the diseases are in particular depression, obsessive compulsive disorders (OCD), obsessive compulsive spectrum disorders (OCSD) and anxiety.
  • the present invention also relates to a pharmaceutical preparation according to the invention which, in addition to the substance and / or mixture of substances according to the invention, may also contain carriers and / or auxiliaries and — optionally — further active substances, preferably CNS-active substances.
  • the medicaments can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active substances.
  • the substance and / or the mixture of substances is generally administered in analogy to known preparations, preferably in doses between about 0.1 and 500 mg, in particular between 5 and 300 mg per dosage unit.
  • the daily dosage is preferably between about 0.01 and 250 mg / kg, in particular between 0.02 and 100 mg / kg body weight.
  • the substance and / or the substance mixture is preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
  • the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
  • the specific dose for each particular patient depends on a variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination, combination of drugs and The severity of the disease to which the therapy applies. Oral application is preferred.
  • the two components of the mixture of substances can be dosed independently of one another in relation to one another.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application. NEN and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, coated tablets, capsules, syrups, juices, drops or suppositories are used in particular for enteral administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for parenteral administration, and ointments, creams or powders for topical application.
  • the new compounds can also be lyophilized and the resulting lyophilisates used, for example, for the production of injection preparations.
  • the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colorants, flavorings and / or flavorings. If desired, they can also contain one or more other active ingredients, e.g. one or more vitamins.
  • auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colorants, flavorings and / or flavorings.
  • they can also contain one or more other active ingredients, e.g. one or more vitamins.
  • a solution of 100 g of a substance and / or substance mixture according to the invention and 5 g of disodium hydrogenphosphate in 3 l of double-distilled water is adjusted to pH 6.5 with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized and sealed sterile. Each injection jar contains 5 mg substance mixture.
  • Example A2 suppositories
  • Example A3 Solution A solution of 1 prepares g of a material of the invention / or composition, 9:38 g of NaH 2 P0 4 x 2 H 2 O, 28.48 g NaH 2 PO 4 x 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml twice and distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.
  • Example A4 ointment
  • 500 mg of a substance and / or substance mixture according to the invention are mixed with 99.5 g of petroleum jelly under aseptic conditions.
  • a mixture of 1 kg of a substance and / or mixture of substances according to the invention, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of mixture of substances.
  • Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
  • a solution of 1 kg of a substance and / or substance mixture according to the invention in 60 l of double-distilled water is filled into ampoules, lyophilized under aseptic conditions and sealed sterile. Each ampoule contains 10 mg substance mixture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des associations d'inhibiteurs de reprise de sérotonine et d'agonistes d'imidazoline-l2 comme unités chimiques séparées ou les deux propriétés réunies dans une molécule. L'invention concerne également leur utilisation pour la production de médicaments destinés au traitement de la dépression, troubles obsessionnels (troubles obsessionnels compulsifs, OCD), troubles de spectre obsessionnel compulsif (OCSD) et autres troubles anxieux.
EP04803903A 2004-01-19 2004-12-15 Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb Withdrawn EP1708754A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004002638A DE102004002638A1 (de) 2004-01-19 2004-01-19 Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten
PCT/EP2004/014284 WO2005067969A2 (fr) 2004-01-19 2004-12-15 Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i2

Publications (1)

Publication Number Publication Date
EP1708754A2 true EP1708754A2 (fr) 2006-10-11

Family

ID=34778082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04803903A Withdrawn EP1708754A2 (fr) 2004-01-19 2004-12-15 Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb

Country Status (7)

Country Link
US (1) US20080027140A1 (fr)
EP (1) EP1708754A2 (fr)
JP (1) JP4728257B2 (fr)
AU (1) AU2004313648B2 (fr)
CA (1) CA2553629A1 (fr)
DE (1) DE102004002638A1 (fr)
WO (1) WO2005067969A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846430T1 (sl) 2005-02-09 2009-08-31 Basilea Pharmaceutica Ag Novi makrolidi
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914235A (en) * 1996-10-11 1999-06-22 Eli Lilly And Company Potentiation of 3 H! 2-(2-benzofuranyl)-2-imidazoline (BFI) binding sites in human tissue by tranylcypromine (TCP)
WO1999020279A1 (fr) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentialisation de produits pharmaceutiques
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
AU4919099A (en) * 1998-07-11 2000-02-01 University Of Bristol, The Compounds having activity at imidazoline receptors
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
HU0200980D0 (fr) * 2002-03-14 2002-05-29 Gabor S Pal Dr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005067969A2 *

Also Published As

Publication number Publication date
JP4728257B2 (ja) 2011-07-20
AU2004313648A1 (en) 2005-07-28
WO2005067969A2 (fr) 2005-07-28
DE102004002638A1 (de) 2005-08-18
CA2553629A1 (fr) 2005-07-28
AU2004313648B2 (en) 2010-09-30
US20080027140A1 (en) 2008-01-31
WO2005067969A3 (fr) 2007-04-05
JP2007520475A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
DE69710390T2 (de) Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren
DE60103556T3 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
DE69930243T2 (de) Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu
DE69034149T2 (de) Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen
DE60016602T2 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE60120104T2 (de) Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE69715899T2 (de) Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
DE60008374T2 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
DE60004348T2 (de) Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate
AT10974U1 (de) Verwendung von enantiomer-reinem escitalopram
DE69725345T2 (de) Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden
DE69824313T2 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
DE10393729T5 (de) Verfahren zur Behandlung von Emesis
DE69129750T2 (de) Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung
EP1461042B1 (fr) Utilisation de desoxypeganine pour le traitement de la depression clinique
DE2362123A1 (de) Pharmazeutische zubereitungen
DE60217870T2 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
EP1513533A2 (fr) Combinaison d'agents actifs pharmaceutiques et utilisation
DE60114419T2 (de) Neue verwendung von (r)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)-chromane und ihrer physiologisch verträglichen salze
EP1708754A2 (fr) Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb
DE60100431T2 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
DE60220825T2 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DD297557A5 (de) Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE10318714B4 (de) Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17Q First examination report despatched

Effective date: 20091201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120703